B Zwissler, G Kemming, O Habler, M Kleen, M Merkel, M Haller, J Briegel, M Welte and K Peter
Department of Anesthesiology, Ludwig-Maximilians-Universitat Munchen, Germany.

Inhalation of nitric oxide (NO) and prostacyclin (PGI2) may induce selective pulmonary vasodilation and-by improving ventilation-perfusion ratio in ventilated areas of the lung-increase Pao2 in patients with acute lung injury. To assess the therapeutic efficacy of both compounds, dose-response curves were established in patients with adult respiratory distress syndrome (ARDS). Patients received both PGI2 (doses of 1, 10, and 25 ng/kg/min) and NO (concentrations of 1, 4, and 8 ppm). Cardiorespiratory parameters were assessed at control, at each drug concentration, and after withdrawal of NO and PGI2. PGI2 resulted in a significant, dose-dependent and selective reduction of pulmonary artery pressure (PAP) from 35.1 +/- 6.3 mm Hg at control to 33.1 +/- 4.8 (1 ng/kg/min), 31.3 +/- 4.8 mm Hg (10 ng/kg/min) and 29.6 +/- 4.5 mm Hg (25 ng/kg/min), respectively. Inhaled NO reduced PAP from 34.5 +/- 5.6 to 32.1 +/- 5.9 mm Hg at 4 ppm, and to 31.8 +/- 6.1 mm Hg at 8 ppm, respectively, with no effect at 1 ppm. Pao2/Flo2 ratio increased from 105 +/- 37 to 125 +/- 56 mm Hg (range of increase: 0 to 57 mm Hg) at PGI2 10 ng/kg/min and to 131 +/- 63 mm Hg (range: -5 to 89 mm Hg) at 25 ng/kg/min with no effect at 1 ng/kg/min. NO improved Pao2 (e.g., from 116 +/- 47 to 167 +/- 86 mm Hg at 8 ppm) and reduced intrapulmonary shunt at all doses tested. We conclude that both inhaled PGI2 and NO may induce selective pulmonary vasodilation and increase Pao2 in severe ARDS.

This article has been cited by other articles:

				I. B. Copland, D. Reynaud, C. Pace-Asciak, and M. Post Mechanotransduction of stretch-induced prostanoid release by fetal lung epithelial cells Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L487 - L495. [Abstract] [Full Text] [PDF]

				M. Cepkova and M. A. Matthay Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress Syndrome J Intensive Care Med, May 1, 2006; 21(3): 119 - 143. [Abstract] [PDF]

				S. K. Vora, R. A. Asherson, and D. Erkan Catastrophic Antiphospholipid Syndrome J Intensive Care Med, May 1, 2006; 21(3): 144 - 159. [Abstract] [PDF]

				R. Jain and A. DalNogare Pharmacological Therapy for Acute Respiratory Distress Syndrome Mayo Clin. Proc., February 1, 2006; 81(2): 205 - 212. [Abstract] [Full Text] [PDF]

				M. J.D. Griffiths and T. W. Evans Inhaled Nitric Oxide Therapy in Adults N. Engl. J. Med., December 22, 2005; 353(25): 2683 - 2695. [Full Text] [PDF]

				B. S. Burleson and E. D. Maki Acute Respiratory Distress Syndrome Journal of Pharmacy Practice, April 1, 2005; 18(2): 118 - 131. [Abstract] [PDF]

				S. M. Lowson Alternatives to nitric oxide Br. Med. Bull., November 5, 2004; 70(1): 119 - 131. [Abstract] [Full Text] [PDF]

				C. J. De Wet, D. G. Affleck, E. Jacobsohn, M. S. Avidan, H. Tymkew, L. L. Hill, P. B. Zanaboni, N. Moazami, and J. R. Smith Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1058 - 1067. [Abstract] [Full Text] [PDF]

				D. J. Reily, E. Tollok, K. Mallitz, C. W. Hanson III, and B. D. Fuchs Successful Aeromedical Transport Using Inhaled Prostacyclin for a Patient With Life-Threatening Hypoxemia Chest, April 1, 2004; 125(4): 1579 - 1581. [Abstract] [Full Text] [PDF]

				S. M. Lowson Nitric Oxide Signaling and Clinical Alternatives to Nitric Oxide Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 239 - 252. [Abstract] [PDF]

				R.T. Schermuly, H. Leuchte, H.A. Ghofrani, N. Weissmann, F. Rose, M. Kohstall, H. Olschewski, C. Schudt, F. Grimminger, W. Seeger, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure Eur. Respir. J., August 1, 2003; 22(2): 342 - 347. [Abstract] [Full Text] [PDF]

				E.D. Moloney and T.W. Evans Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome Eur. Respir. J., April 1, 2003; 21(4): 720 - 727. [Abstract] [Full Text] [PDF]

				M. Hache, A. Denault, S. Belisle, D. Robitaille, P. Couture, P. Sheridan, M. Pellerin, D. Babin, N. Noel, M.-C. Guertin, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 642 - 649. [Abstract] [Full Text] [PDF]

				J Cranshaw, M J D Griffiths, and T W Evans The pulmonary physician in critical care c 9: Non-ventilatory strategies in ARDS Thorax, September 1, 2002; 57(9): 823 - 829. [Abstract] [Full Text] [PDF]

				H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, S. Nikkho, R. Speich, M. M. Hoeper, J. Behr, et al. Inhaled Iloprost for Severe Pulmonary Hypertension N. Engl. J. Med., August 1, 2002; 347(5): 322 - 329. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, H. Leuchte, F. Grimminger, W. Seeger, and D. Walmrath Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1361 - L1368. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225. [Abstract] [Full Text] [PDF]

				P. C. Rimensberger, I. Spahr-Schopfer, M. Berner, E. Jaeggi, A. Kalangos, B. Friedli, and M. Beghetti Inhaled Nitric Oxide Versus Aerosolized Iloprost in Secondary Pulmonary Hypertension in Children With Congenital Heart Disease : Vasodilator Capacity and Cellular Mechanisms Circulation, January 30, 2001; 103(4): 544 - 548. [Abstract] [Full Text] [PDF]

				R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure Anesth. Analg., August 1, 2000; 91(2): 291 - 295. [Abstract] [Full Text] [PDF]

				H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group* Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Ann Intern Med, March 21, 2000; 132(6): 435 - 443. [Abstract] [Full Text] [PDF]

				P. V. van Heerden, A. Barden, N. Michalopoulos, M. K. Bulsara, and B. L. Roberts Dose-Response to Inhaled Aerosolized Prostacyclin for Hypoxemia Due to ARDS Chest, March 1, 2000; 117(3): 819 - 827. [Abstract] [Full Text] [PDF]

				T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF]

				S. Stott Recent advances: Recent advances in intensive care BMJ, February 5, 2000; 320(7231): 358 - 361. [Full Text]

				R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520. [Abstract] [Full Text]

				R. T. SCHERMULY, H. A. GHOFRANI, B. ENKE, N. WEISSMANN, F. GRIMMINGER, W. SEEGER, C. SCHUDT, and D. WALMRATH Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1500 - 1506. [Abstract] [Full Text]

				H. OLSCHEWSKI, H. ARDESCHIR GHOFRANI, D. WALMRATH, R. SCHERMULY, B. TEMMESFELD-WOLLBRÜCK, F. GRIMMINGER, and W. SEEGER Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 600 - 607. [Abstract] [Full Text]

				M. Moutafis, N. Dalibon, A. Colchen, and M. Fischler Improving Oxygenation During Bronchopulmonary Lavage Using Nitric Oxide Inhalation and Almitrine Infusion Anesth. Analg., August 1, 1999; 89(2): 302 - 302. [Full Text] [PDF]

				L. L. Hill and R. G. Pearl Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension J Appl Physiol, April 1, 1999; 86(4): 1160 - 1164. [Abstract] [Full Text] [PDF]

				A. P. Wheeler and G. R. Bernard Treating Patients with Severe Sepsis N. Engl. J. Med., January 21, 1999; 340(3): 207 - 214. [Full Text] [PDF]

				F. HINDER, H. D. STUBBE, H. VAN AKEN, R. WAURICK, M. BOOKE, and J. MEYER Role of Nitric Oxide in Sepsis-associated Pulmonary Edema Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 252 - 257. [Abstract] [Full Text]

				C. S. Rayhrer, T. D. Edmisten, G. A. Cephas, C. G. Tribble, I. L. Kron, and J. S. Young Nitric Oxide Potentiates Acute Lung Injury in an Isolated Rabbit Lung Model Ann. Thorac. Surg., April 1, 1998; 65(4): 935 - 938. [Abstract] [Full Text] [PDF]

				J. R. MICHAEL, R. G. BARTON, J. R. SAFFLE, M. MONE, B. A. MARKEWITZ, K. HILLIER, M. R. ELSTAD, E. J. CAMPBELL, B. E. TROYER, R. E. WHATLEY, et al. Inhaled Nitric Oxide Versus Conventional Therapy . Effect on Oxygenation in ARDS Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1372 - 1380. [Abstract] [Full Text]